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Complexos de inclusões e misturas físicas contendo mistura isomérica E/Z (50:50) de 3-(4’-
bromo-[1,1’-bifenil]-4-il)-3-(4-bromofenil)-N,N-dimetil-2-propen-1-amina (BBAP) e β-ciclodextrina
(β-CD) nas proporções molares de 1:1 e 1:2 foram analisados por microscopia eletrônica de varredura
(SEM). O perfil de dissolução do BBAP e dos complexos de inclusões foram também avaliados
durante 6 horas. Por microscopia eletrônica de varredura foi possível observar os complexos de
inclusões formados entre BBAP e β-CD por co-evaporação nas proporções molares de 1:1 e 1:2.
Como previamente detectado pela caracterização físico-química, na mistura física não se observou a
presença de complexo de inclusão. Os estudos de dissolução mostraram que os complexos de inclusões
1:1 e 1:2 liberaram, respectivamente 49.07 ± 1.48 e 40.26 ± 3.90% de BBAP durante 6 horas. BBAP
na forma livre foi menos solúvel que os complexos de inclusões e atingiu 9.00 ± 0.75% de dissolução.
Os ensaios de citotoxicidade em macrófagos J774 e em uma linhagem de células fibroblásticas de
pulmão (V79) indicaram que o BBAP não exibiu efeito tóxico adicional quando complexado com
β-CD. Entretanto, os complexos de inclusões foram menos tóxicos para células V79 que BBAP na
forma livre. Os complexos de inclusões BBAP/β-CD foram mais efetivos (CIM) que o composto
livre em várias cepas de micobactérias. Resultados semelhantes foram observados sobre M. tuberculosis
H37Rv intracelular para os complexos de inclusões BBAP/β-CD e rifampicina, uma droga anti-
tuberculose de primeira linha.
Inclusion complexes and physical mixtures of isomeric mixture of E/Z (50:50) of 3-(4’-bromo-
[1,1’-biphenyl]-4-yl)-3-(4-bromophenyl)-N,N-dimethyl-2-propen-1-amine (BBAP) and
β-cyclodextrin (β-CD) in the molar proportion of 1:1 and 1:2 were analyzed by scanning electron
microscopy. The dissolution behavior of BBAP and of the inclusion complexes were also evaluated
for six hours. By scanning electron microscopy (SEM), it was possible to observe an inclusion
complex formed between BBAP and β-CD by co-evaporation, either in the molar proportion of 1:1 or
1:2. In the physical mixtures, no complex was observed as previously detected by physicochemical
analysis. The dissolution studies showed that the inclusion complexes BBAP/β-CD 1:1 and 1:2
released respectively 49.07 ± 1.48 and 40.26 ± 3.90% of BBAP during six hours. Free BBAP was
less soluble than the inclusion complex and reached 9.00 ± 0.75% of dissolution. Biological assays,
such as cytotoxicity to J774 macrophages and to a permanent lung fibroblast cell line (V79), indicated
that the BBAP does not exhibit any additional toxic effect with the β-CD complexes. However, the
complexes were less cytotoxic to V79 cells than the free form. The BBAP/β-CD inclusion complexes
were more effective (MIC) than the free compound on several mycobacteria strains. Similar behavior
was observed for BBAP/β-CD complexes and rifampicin, a front-line antitubercular drug, on M.
tuberculosis H37Rv growing inside J774 macrophages.
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Introduction
CDs are cyclic oligosaccharides named α, β and γ-CD,
and have a relatively hydrophobic central cavity and a
hydrophilic outer surface. There has been great interest in
CD inclusion complexes, as a means of increasing the
solubility and dissolution rate of poorly soluble drugs.
Water-insoluble drugs are usually characterized by a low
bioavailability, since their absorption is dissolution rate-
limited and consequently slow. CDs were considered good
candidates for the enhancement of the dissolution rate of
insoluble drugs.1
As previously reported,2-6 among ten 2-propen-1-amine
derivatives, 3-(4’-Bromo-[1,1’-biphenyl]-4-yl)-3-(4-
bromophenyl)-N,N-dimethyl-2-propen-1-amine (BBAP), is
a compound with promising pharmacological activities
against pathogenic trypanosomatids and mycobacteria.
However, it presents the disadvantages of toxicity towards
mammalian cells and no solubility in water. In order to
improve the solubility of BBAP, inclusion complex and
physical mixture containing BBAP (as a mixture of
geometric isomers) and β-CD were previously prepared
and physicochemically characterized. An inclusion
complex was obtained between BBAP and β-CD after co-
evaporation, and no inclusion complex was formed in the
physical mixture.7
In this study, the morphology of the inclusion complex
and of the physical mixture between BBAP and β-CD were
analyzed by scanning electron microscopy (SEM). The
solubility of BBAP was evaluated in presence of different
concentrations of β-CD and the extension of dissolution
in water of the inclusion complexes was determined.
Biological assays were also performed in order to evaluate
the cytotoxicity of the inclusion complexes and the
antimycobacterial activity.
Materials and Methods
Materials
β-CD was purchased from Sigma and the ethanol used
was of analytical grade. Inclusion complexes and physical
mixtures were prepared and physicochemically
characterized following the procedure previously
described.7 Briefly, BBAP (as a mixture of geometric
isomers 50:50) and β-CD in the molar proportion of 1:1
and 1:2 were dissolved in a mixture of water/ethanol
(30:100) and the solvent was evaporated at 80 °C under
reduced pressure. Physical mixtures of BBAP and β-CD in
the molar proportion of 1:1 and 1:2 were uniformly and
gently mixed without milling in order to avoid any grinding
action in the mixture. BBAP, inclusion complexes and the
physical mixture were completely dried under high
vacuum at room temperature and stored in a desiccator
over silica gel until the moment of use.
Scanning electron microscopy
Scanning Electron Microscopy (SEM) of the BBAP, β-
CD, physical mixtures (BBAP/β-CD 1:1 and 1:2), and of
the inclusion complexes (BBAP/β-CD 1:1 and 1:2) were
performed using a JEOL JSM – T300 microscope in order
to obtain the topographic images, through secondary
electrons with a tension of 20 KV. Samples were mounted
using double-sided adhesive coated aluminum stubs and
vacuum-coated with gold for 100 seconds to render them
electrically conductive.
Phase solubility studies
The phase solubility studies were performed according
to the method reported by Higuchi and Connors.8 BBAP
(5mg) was added to the aqueous solution (10 mL)
containing different concentrations of β-CD ( 0, 0.2, 0.4,
0.6, 0.8, 1.0, 1.2, 1.4, 1.6 and 1.8 mmol L-1). The
experiments were carried out in triplicate. Solutions were
shaked at 25 °C for 48 hours. This time of reaction was
chosen from preliminary kinetic studies (not shown). After
that, the suspensions were filtered through a 0.22 µm
Millipore glass fiber membrane filter, and the concentration
of BBAP in the filtrate was determined by spectro-
photometer at 266 nm.
The apparent 1:1 stability constant (Ks) was calculated
from the straight line of the phase-solubility diagram,
following the equation proposed by Higuchi and Connors:
Ks= slope/intercept (1-slope), where S
o
 is the BBAP
equilibrium concentration in aqueous solution in the
absence of β-CD, and slope is the slope of the phase
solubility diagram.
Dissolution studies
The dissolution behavior of both, BBAP/β-CD 1:1 and
BBAP/β-CD 1:2 complexes were compared with that of
pure BBAP. Tests were carried out according to USP23
Method. The dissolution media was deionized water, the
stirring speed was 50 rpm/min and the temperature was
maintained at 37 °C and the samples were stirred for six
hours. The amount of each binary system employed
followed the molar ratio 1:1 and 1:2. Aliquots of 2 mL
were withdrawn at various time intervals, filtered through
a 0.22 µm membrane filter and immediately replaced with
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an equal volume of water. The amount of BBAP dissolved
was appropriately diluted in ethanol and the concentration
was determined by spectrophotometry at 266 nm.
BBAP concentration was determined by comparison
with a standard curve of BBAP in ethanol. The measu-
rements were evaluated in duplicate in two independent
assays. A correction was applied to compensate the
cumulative dilution caused by replacement of water to the
samples.
Biological assays
Extracellular antimicrobial susceptibility testing. Tests
were performed by the microplate Alamar Blue assay, as
previously described.9 M. tuberculosis H37Rv ATCC
27294, M. tuberculosis H37Ra ATCC 25177, M. avium
ATCC 15769, M. kansasii ATCC 12478, M. intracellulare
ATCC 25169, and M. malmoense ATCC 29571 were grown
in Loweinstein-Jensen medium at 37 °C for 3 weeks and
subcultured in Middlebrook 7H9 broth medium at 37 °C
for 10 days, until a 1.0 McFarland turbidity standard was
reached. Suspensions of mycobacteria were diluted 1:25
in Middlebrook 7H9 broth medium and 100 µL were seeded
in a 96-well microplate (4x105 mycobacteria mL-1)
containing 100 µL of serial dilutions of the samples. Plates
were incubated at 37°C for 6 days. Following that, 25 µL
of a mixture 1:1 (v/v) of Alamar Blue reagent and 10%
Tween 80 were added to the wells and plates were
reincubated at 37 °C. After 24 hours, a change in color,
from blue to pink, was observed in the wells where
mycobacteria grew. Solutions of the samples were prepared
in dimethylsulfoxide (DMSO - Sigma Chem. Co, MO, USA)
and sterilized by passage through a 0.22 µm PFTE filter.
Dilutions in the range from 0.001 to 0.640 mmol L-1 were
performed in Middlebrook 7H9 broth medium with the
final concentration of DMSO never exceeding 0.3%.
Rifampicin was used as reference drug. Control wells
consisted of either bacterium only, drugs with medium or
only medium. The visual MICs were defined as the lowest
drug concentration that prevented a color change from
blue to pink.
Intracellular Antimicrobial susceptibility testing. J774
macrophages were harvested and plated at a concentration
of 5x105 cells per well in 24-well tissue culture plates. After
overnight incubation, J774 macrophages were overlaid with
a suspension of M. tuberculosis H37Rv (5x106 mycobacteria
mL-1) adjusted to yield a multiplicity of infection of 10
bacteria per macrophage. Cells were infected for 4 hours
and washed with phosphate-buffered saline (PBS), pH 7.4,
to eliminate unbound mycobacteria.10 M. tuberculosis
H37Rv-infected cells were re-fed with culture medium and
then incubated with different concentrations of the samples
ranging from 0.001 to 0.080 mmol L-1. Rifampicin at 0.012
mmol L-1 and RPMI 1640 medium were used as controls.
After 72 h, cells were washed with culture medium to
eliminate extracellular bacteria and lysed by addition of 1
ml of 0.25% (m/v) sodium dodecyl sulfate in PBS, pH 7.4.
The lysates were serially diluted and 100 µL aliquots were
dispersed onto 7H10 agar plates. The colony formation units
(CFU) of M. tuberculosis H37Rv were counted 2-4 weeks
after incubation at 37 °C.
Cytotoxicity to mammalian cells. Cytotoxicity of the
preparations was determined by a multi-endpoint method.
The cytotoxic effect, expressed as cell viability, was
assayed on J774 macrophages and in a permanent lung
fibroblast cell line derived from Chinese hamsters (V79).
Stock solutions of the samples were prepared in DMSO,
and diluted in Dulbecco’s modification of Eagle’s medium
(DMEM) or RPMI 1640 medium without phenol red. The
final concentration of the solvent in the assay was less
than 0.3%. The controls received no drugs and each drug
concentration was tested in six (J774 cells) or eight
replicates (V79 cells), and repeated three times in separate
experiments. After 24 hours of incubation, three
independent endpoints for cytotoxicity were evaluated:
nucleic acid content (NAC), reduction of 3-(4,5-
dimethylthiazole-2-yl)-2,5-diphenyl tetrazolium bromide
(MTT), and neutral red uptake (NRU).
J774 Cells: J774 cells were grown as monolayers in
RPMI 1640 medium supplemented with 10% heat-
inactivated fetal calf serum (FCS), 100 IU mL-1 penicillin
and 100 µg mL-1 streptomycin in a humidified incubator
with 5% CO2 in air at 37 °C. Cells were plated in 96-well
plates at the concentration of 2x106 cells mL-1. The medium
was removed 12 hours after cell seeding and replaced by a
medium containing the samples at concentrations ranging
from 0 to 0.160 mmol L-1. Cells were exposed for 24 hours
to test medium with or without the drugs (control).
V79 Fibroblasts: V79 fibroblasts were grown as
monolayers in Dulbecco’s modification of Eagle’s medium
(DMEM), supplemented with 10% heat-inactivated fetal
calf serum (FCS), 100 IU mL-1 penicillin and 100 µg mL-1
streptomycin in a humidified incubator with 5% CO2 in
air at 37 °C. Cells were plated at the density of 3x104 cells
mL-1 in 96-well plates. The medium was removed 48 hours
after cell seeding and replaced with medium containing
the samples at concentrations ranging from 0 to
0.060 mmol L-1. Samples were first dissolved in DMSO
and then diluted in DMEM. Cells were exposed for 24
hours to test medium with or without drugs (control).
NAC: The cell number in control and treated wells was
estimated from their total nucleic acid content according
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to Cingi et al.11 After exposition to samples, the cells were
washed twice with cold PBS, pH=7.4, and a soluble
nucleotide pool was extracted with cold ethanol. Cell
monolayers were then dissolved in 0.1 mL of NaOH (0.5
mol L-1) and incubated at 37 °C for 1 hour and absorbance
was read at 260 nm. The results are expressed by
comparison of absorbance between cells treated with drugs
and controls (no drugs).
MTT: The tetrazolium reduction assay was performed
according to Denizot and Lang.12 Briefly, after exposition
to the drugs, cells were washed once with PBS, pH=7.4,
and 0.1 mL of serum-free medium containing MTT (1 mg
mL-1 for V79 cells and 0.5 mg mL-1 for J774 cells) was
added to each well. After incubation for 4 h, the supernatant
was removed and the blue formazan product obtained was
dissolved in 0.1 mL of ethanol for V79 cells and 0.1 mL of
isopropanol acid (HCl 0.1 mol L-1) for J774 cells. Plates
were stirred for 15 min on a microtiter plate shaker and
absorbance was read at 570 nm.
NRU: The neutral red uptake assay was performed
according to Borenfreund and Puerner.13 After exposition
to the drugs, cells were incubated for 4 hours with serum-
free medium containing neutral red (50 µg mL-1) and then
quickly washed with PBS-Ca2+ (PBS plus 1 mmol L-1 of
CaCl2 and 2 mmol L-1 of MgCl2), pH 7.4. The dye was
dissolved in 0.1 mL of 1% (v/v) acetic acid in 50% (v/v)
ethanol and, after agitation on a microtiter plate shaker,
absorbance was read at 540 nm.
Results and Discussion
Scanning electron microscopy
In the morphological analysis, typical crystals of β-CD
were found in many different sizes (Figure 1A). BBAP showed
a wavy domain by SEM (Figure 1B) and an amorphous one
by X-ray diffraction. There was an agglomeration of β-CD
around the BBAP in the physical mixtures of BBAP/β-CD
1:1 (Figure 2A) and 1:2 (Figure 3A). Regarding the co-
evaporated inclusion complex BBAP/β-CD 1:1 (Figure 2B)
and 1:2 (Figure 3B), a compact structure formed by the
aggregation of the crystals was observed. Whereas the
physical mixture showed the crystalline structure of BBAP
and β-CD, the features of both crystals in the inclusion
complex were not easily detectable. Scanning electron
microscopy revealed morphological differences among the
different preparations, contributing to the characterization
of the physical mixtures and of the inclusion complexes
BBAP/β-CD 1:1 and 1:2. These data are in agreement with
previous results,7 showing the presence of inclusion complex
between BBAP and β-CD.
Figure 2. Scanning electron microscopy of physical mixture BBAP/
β-CD 1:1 (A) and inclusion complex of BBAP/β-CD 1:1 (B) - mag-
nification of 750X.
Figure 1. Scanning electron microscopy of β-CD (A) and BBAP (B)
– Magnification of 750X.
686 de Souza et al. J. Braz. Chem. Soc.
Phase solubility studies
The phase solubility diagram for BBAP with β-CD is
shown in Figure 4. In the presence of β-CD the phase
solubility behavior of BBAP followed the AL- type phase
solubility diagrams8 and suggests 1:1 interaction between
BBAP and β-CD. The Ks value obtained was 16.75 M-1 to
β-CD, indicating a weak interaction between BBAP and
β-CD.
Dissolution studies
Dissolution profiles were not performed for the
physical mixtures, since there is no inclusion complex in
these preparations. Figure 5 shows the dissolution behavior
of BBAP and of its inclusion complexes with β-CD. In the
end of the experiment, the percentage of dissolved
BBAP reached 9.00 ± 0.75%. The inclusion complexes
BBAP/β-CD 1:1 and 1:2 showed a similar dissolution
behavior, with respectively 49.07 ± 1.48 and 40.26 ±
3.90% dissolution. At the molar proportion of 1:1,
dissolution was higher than at 1:2. Dissolved amounts of
BBAP from the inclusion complex in the molar proportion
of 1:1 and 1:2 increased respectively 5.45 and 4.47-fold,
compared with pure BBAP at six hours. In these
preparations, β-CD increased the ability of dissolution of
BBAP, as expected.
Biological assays
Extracellular antimicrobial susceptibility testing. Table
1 shows the minimal inhibitory concentration (MIC) of
BBAP and of the inclusion complexes BBAP/β-CD 1:1 and
1:2 against mycobacteria. Either free BBAP or BBAP
complexed with β-CD acting on M. tuberculosis H37Rv
showed the same activity, with MIC around 0.008 mmol L-1.
However, on M. tuberculosis H37Ra, M. avium and M.
kansasii, both 1:1 and 1:2 complexes were at least four
times more effective than the free form of BBAP. Regarding
M. intracellulare, an 8-fold higher activity was observed in
comparison to the free form. A slight difference was observed
with M. malmoense (1.6 fold) compared with the free form.
Figure 5. Dissolution profiles of BBAP (Q), BBAP/β-CD 1:1 (O)
and 1:2 (V), in water at 37 °C during six hours.
Figure 3. Scanning electron microscopy of physical mixture BBAP/
β-CD 1:2 (A) and inclusion complex BBAP/β-CD 1:2 (B) - magni-
fication of 750X.
Figure 4. Solubility of BBAP in water at 25 °C as a function of β-CD
concentration.
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Intracellular antimicrobial susceptibility testing.
Figure 6 shows the effect of free BBAP and of the inclusion
complexes BBAP/ß-CD 1:1 or 1:2 and rifampicin, against
M. tuberculosis H37Rv growth inside J744 macrophages.
Free BBAP significantly reduced the CFU number at 0.080
mmol L-1. Complex 1:1 reduced the CFU number; however
this effect was not significant in all the concentrations
assayed. BBAP/β-CD 1:2 at 0.080 mmol L-1 showed a
significant effect, similar to that of rifampicin at
0.012 mmol L-1.
Cytotoxicity to mammalian cells. Figure 7 shows the
cytotoxicity of free and inclusion complexes of BBAP/β-
CD 1:1 and 1:2 on V79 cells by multi-endpoints NAC,
MTT and NR, respectively. In Figure 7A, it may be
observed that neither the 1:1 nor the 1:2 BBAP/ß-CD
complexes presented significant cytotoxicity (only 10%
of reducing viability at 0.060 mmol L-1), however the free
form was extremely toxic in the nucleic acid content (NAC)
test (IC50 of 0.008 mmol L-1). Similar results were observed
in the neutral red (NR) test (Figure 7C), which showed an
IC50 of 0.011 mmol L-1 in the free form and absence of
cytotoxic effect in the complexes. In the MTT assay (Figure
7B), BBAP/β-CD complex induced a strong enhancement
in MTT reduction, but BBAP was very toxic in its free
form (IC50 0.005 mmol L-1). Some authors14,15 have
suggested that MTT reduction is a measurement of
mitochondrial function, in particular of succinate
dehydrogenase activity, but studies using hepatocytes
Figure 6. Effects of free BBAP and of inclusion complexes BBAP/
β-CD 1:1 or BBAP/β-CD 1:2 and RFP against M. tuberculosis H37Rv
growth inside J774 macrophages. Macrophages were lysed to deter-
mine the CFU of M. tuberculosis H37Rv following the procedure
described in the text. Bars represent mean ± SEM. RPMI 1640 and
Rifampicin (RFP - 0.012 mmol L-1) were used as controls.
Figure 7. Cytotoxicity of free BBAP, inclusion complexes BBAP/β-
CD 1:1 and BBAP/β-CD 1:2 to V79 cells by multiendpoints NAC
(A), MTT (B) and NR (C). BBAP (Q), BBAP/β-CD 1:1 (O), and
BBAP/β-CD 1:2 (V).
Table 1. MICs (mmol L-1) of BBAP, inclusion complex BBAP/β-CD
1:1 and 1:2 on standard mycobacterial strains
Samples (mmol L-1)
Strains BBAP BBAP/β-CD BBAP/β-CD
1:1 1:2
M. tuberculosis H37Rv 0.008 ≤ 0.008 ≤ 0.008
M. tuberculosis H37Ra 0.032 ≤ 0.008 ≤ 0.008
M avium 0.032 ≤ 0.008 ≤ 0.008
M. kansasii 0.032 ≤ 0.008 ≤ 0.008
M. intracellulare 0.064 ≤ 0.008 ≤ 0.008
M. malmoense 0.016 ≤ 0.010 ≤ 0.010
M. tuberculosis H37Rv ATCC 27294, M. tuberculosis H37Ra ATCC
25177, M avium ATCC 15769, M. kansasii ATCC 12478, M.
intracellulare ATCC 25169, M. malmoense ATCC 29571.
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have indicated that it probably assesses the cytosolic
NAD(P)/NAD(P)H redox balance. The MTT assay also
measures cell viability based on endocytosis, a
fundamental feature of most living cells. However, various
factors affecting the endocytosis of MTT, the exocytosis
of MTT formazan, and cellular MTT reductase activity
can influence the reduction of MTT.14,15 This may have
occurred in the inclusion complex.
Figure 8 shows the cytotoxicity of free BBAP and
inclusion complexes 1:1 and 1:2 acting on J774 cells by
multi-endpoint MTT and NR. Figure 8A shows the MTT
assay, where the values for free BBAP, BBAP/β-CD
complexes 1:1 and 1:2 were IC50 0.046, 0.066 and
0.060 mmol L-1, respectively. Meanwhile, in the NR assay
(Figure 8B), IC50 values for BBAP in its free form and in
BBAP/β-CD complex 1:1 and 1:2 were 0.049, 0.060 and
0.059 mmol L-1, respectively. The inclusion complexes
were less toxic than free BBAP on J774 macrophages, but
the IC50 values were very close (IC50 around 0.060 mmol L-1).
The absence of cytotoxic effects induced by the
inclusion complexes compared to free BBAP in V79 cells
and reduction of cytotoxicity on J774 macrophages could
be explained by the solubility differences between the
complexes and the pure form. The complexes are more
hydrophylic than free BBAP and there is a relationship
between cellular toxicity, lipophylicity and electro-
philicity. It is known that lipophylic substances show more
cytotoxic effects than hydrophylic compounds. The toxic
effects of the lipophylic compounds are intrinsically related
to the changes that they induce in the cell membrane
structure.16
Several factors can interfere with chemical cytotoxicity
including concentration of chemical agents, length of
exposure, cell density and cell type. Duration of exposure
(T) and drug concentration (C) are related, although CxT
is not always a slant. Longer exposure can increase
sensitivity beyond that predicted by CxT due to cell cycle
effects and cumulative effect from the agents.14 Thus, BBAP
and inclusion complexes inhibits J774 viability in a similar
way, but the complexes do not cause cytotoxic effects on
V79 cells according to our experimental conditions that
could be influenced by intrinsic characteristics of each
type of cell culture evaluated.
These data show that, although BBAP/β-CD inclusion
complexes are more effective than free BBAP on
mycobacteria extra and/or intracellularly, the respective
concentrations are close to the toxic in vitro concentration.
Table 2 expresses the selectivity index (SI) ratio IC50 for
J774 macrophages in the MTT assay over MIC for
extracellular M. tuberculosis H37Rv (IC50/MIC). The SI
values determined were 5.75, 8.25 and 7.5 for free BBAP,
inclusion complexes BBAP/β-CD 1:1 and 1:2, respec-
tively. Previous reports indicated that, for a drug to be
considered effective and good candidate against
tuberculosis, its SI should be higher than 10.
Conclusions
An inclusion complex formed between BBAP and β-
CD by co-evaporation, either at the molar proportion of
1:1 or 1:2 was previously characterized and now observed
Table 2. Selectivity index (SI) of BBAP, inclusion complex BBAP/
β-CD 1:1 and 1:2 (SI) for antimycobacterial activity in vitro
Samples MIC IC50 (MTT) SI=IC50/MIC
(mmol L-1) (mmol L-1)
BBAP 0.008 0.046 5.75
BBAP/β-CD 1:1 ≤ 0.008 0.066 8.25
BBAP/β-CD 1:2 ≤ 0.008 0.060 7.50
MIC = corresponds to the MIC on M. tuberculosis H37Rv; IC50 =
corresponds to the IC50 on J774 macrophages by the MTT assay; SI
= IC50/MIC.
Figure 8. Cytotoxicity of free BBAP, inclusion complexes BBAP/β-
CD 1:1, and BBAP/β-CD 1:2 to J774 cells by multiendpoints MTT
(A) and NR (B). BBAP (Q), BBAP/b-CD 1:1 (O) and BBAP/β-CD
1:2 (V).
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by SEM. In the physical mixtures, no complex was
observed. Dissolution studies showed that the inclusion
of BBAP in the β-CD cavity at the molar proportion of 1:1
and 1:2 increased the release of BBAP, which is important
for biological activity.
Biological assays regarding cytotoxicity towards
mammalian cells (J774) and towards a permanent lung
fibroblast cell line (V79) indicated that BBAP did not
exhibit any additional toxic effect with the β-CD
complexes. As to V79 cells, the complexes were not
cytotoxic to these cells, compared to the free form. This
result is important, since there is a correlation between the
IC50 values and the DL50 determined on animals, therefore
these complexes would probably be less toxic in vivo than
the free form. Cytoxicity assays on J774 cells were
important to determine whether the preparations were toxic
to the cells, since mycobacteria are intracellular
microorganisms. The BBAP/β-CD complexes were more
effective (MIC) than the free compound on several
tuberculosis strains. Similar behavior of the inclusion
complexes BBAP/β-CD (1:1 and 1:2) and rifampicin, a
front-line antitubercular drug, was observed for M.
tuberculosis H37Rv growing inside J774 macrophages.
These results indicate that inclusion complexes are
better pharmacological formulations in comparison to the
free form, since they are less cytotoxic and more effective
against mycobacteria. New formulations using other CD
derivatives should be investigated, in order to obtain a
higher selectivity expressed by SI values.
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